Abstract
Objective: In our previous study, we showed that Bacillus Calmette-Guerin (BCG)- activated macrophages have the ability to directly kill tumor cells. One of the main properties of these macrophages is the high expression of tripartite motif family protein 59 (TRIM59). This study was conducted to investigate the mechanism of BCG-induced TRIM59 expression on macrophages and to identify the subcellular localization of TRIM59.
Methods: TRIM59 expression and TNF-α secretion were compared in RAW264.7 macrophage cells that were stimulated using BCG with or without Toll-like receptor 2/4 (TLR2/4)-neutralizing antibodies. Next, small interfering RNA (siRNA) was used to down-regulated interferon regulatory factor 5 (IRF5) gene expression in RAW264.7 cells. Transfected cells were stimulated with BCG, after which TRIM59 expression and TNF-α secretion were evaluated in cells pre-treated with siRNA or scramble control. After treatments, supernatants were co-cultured with MCA207, and cell viabilities were determined. Moreover, BCG-stimulated RAW264.7 cells were stained for TRIM59 and F4/80 expression.
Results: In this study, we showed that TRIM59 was expressed on the membrane of RAW264.7 cells. After blocking TLR2/4, treatment with BCG failed to induce the expression of TRIM59, IRF5, and TNF-α on RAW264.7 cells. In addition, down-regulation of IRF5 inhibited TRIM59 and TNF-α expression.
Conclusion: Our study showed that TRIM59 is a membrane protein, and that BCG treatment upregulated TRIM59 expression on macrophages via TLR2/4 and IRF5 pathways.
Graphical Abstract
Protein & Peptide Letters
Title:BCG Increased Membrane Expression of TRIM59 Through the TLR2/ TLR4/IRF5 Pathway in RAW264.7 Macrophages
Volume: 24 Issue: 8
Author(s): Zheng Jin, Yuan Tian , Dongmei Yan , Dong Li and Xun Zhu *
Affiliation:
- Department of Immunology, College of basic Medical Sciences, Jilin University, Xinmin Street 126#, Changchun, Jilin,China
Keywords: BCG, IRF5, TRIM59, TLR2, TLR4, macrophages.
Abstract: Objective: In our previous study, we showed that Bacillus Calmette-Guerin (BCG)- activated macrophages have the ability to directly kill tumor cells. One of the main properties of these macrophages is the high expression of tripartite motif family protein 59 (TRIM59). This study was conducted to investigate the mechanism of BCG-induced TRIM59 expression on macrophages and to identify the subcellular localization of TRIM59.
Methods: TRIM59 expression and TNF-α secretion were compared in RAW264.7 macrophage cells that were stimulated using BCG with or without Toll-like receptor 2/4 (TLR2/4)-neutralizing antibodies. Next, small interfering RNA (siRNA) was used to down-regulated interferon regulatory factor 5 (IRF5) gene expression in RAW264.7 cells. Transfected cells were stimulated with BCG, after which TRIM59 expression and TNF-α secretion were evaluated in cells pre-treated with siRNA or scramble control. After treatments, supernatants were co-cultured with MCA207, and cell viabilities were determined. Moreover, BCG-stimulated RAW264.7 cells were stained for TRIM59 and F4/80 expression.
Results: In this study, we showed that TRIM59 was expressed on the membrane of RAW264.7 cells. After blocking TLR2/4, treatment with BCG failed to induce the expression of TRIM59, IRF5, and TNF-α on RAW264.7 cells. In addition, down-regulation of IRF5 inhibited TRIM59 and TNF-α expression.
Conclusion: Our study showed that TRIM59 is a membrane protein, and that BCG treatment upregulated TRIM59 expression on macrophages via TLR2/4 and IRF5 pathways.
Export Options
About this article
Cite this article as:
Jin Zheng , Tian Yuan , Yan Dongmei , Li Dong and Zhu Xun *, BCG Increased Membrane Expression of TRIM59 Through the TLR2/ TLR4/IRF5 Pathway in RAW264.7 Macrophages, Protein & Peptide Letters 2017; 24 (8) . https://dx.doi.org/10.2174/0929866524666170818155524
DOI https://dx.doi.org/10.2174/0929866524666170818155524 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin Metabolism in the Central Nervous System
Current Neuropharmacology Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potentials of Triterpenes in Diabetes and its Associated Complications
Current Topics in Medicinal Chemistry Epicardial Adipose Tissue As New Cardio-Metabolic Risk Marker and Potential Therapeutic Target in the Metabolic Syndrome
Current Pharmaceutical Design Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Current Medicinal Chemistry The Impact of Infection on the Incidence of Autoimmune Disease
Current Topics in Medicinal Chemistry Restoration of Transgene Expression in Hematopoietic Cells with Drug-Selectable Marker Genes
Current Gene Therapy Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Atherosclerosis Neovascularization and Imaging
Current Molecular Medicine Cellular Mechanisms of the Protective Effect of Polyphenols on the Neurovascular Unit in Strokes
Cardiovascular & Hematological Agents in Medicinal Chemistry γ-Secretase as a Target for Alzheimers Disease
Current Topics in Medicinal Chemistry Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1)
Current Medicinal Chemistry PTI-609: A Novel Analgesic that Binds Filamin A to Control Opioid Signaling
Recent Patents on CNS Drug Discovery (Discontinued) Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued) Neurogenic Inflammation and Asthma
Inflammation & Allergy - Drug Targets (Discontinued) New Vessel Formation in the Central Nervous System During Tumor Growth, Vascular Malformations, and Moyamoya
Current Neurovascular Research Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Effects of Secondhand Smoke on Thyroid Function
Inflammation & Allergy - Drug Targets (Discontinued) P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design